

## **Orphazyme, joint portfolio company of ALS Investment Fund and LSP, raises approximately €80 million in oversubscribed IPO**

Amsterdam, The Netherlands - 16 November 2017 – the ALS Investment Fund proudly announces that its portfolio company Orphazyme was successfully listed on the Nasdaq Copenhagen, Denmark, raising approximately €80 million after the pricing of DKK 80 per share, corresponding to a post-money market cap of DKK 1,594 million (€214 million). The IPO was oversubscribed several times. The shares are trading under the (permanent) ticker symbol “ORPHA DC Equity”.

The ALS Investment Fund invested, through a joint investment vehicle with LSP, in the company’s Series B Extension round in March 2017. Martijn Kleijwegt, Managing Partner at LSP and Board Member at Orphazyme, commented: “LSP and the ALS Investment Fund believe that Orphazyme is at a time when the company is pushing the boundaries and bringing its technology to a wide range of diseases that have devastating consequences for the sufferers and their loved ones. This has now, only 8 months later, resulted in Orphazyme’s IPO being one of the most successful IPOs for Biotech in Europe with 80M€ raised before the 15% overallotment option. An excellent achievement for the company, proving Orphazyme’s leading position in the rare disease space.”

Felix von Coerper, Managing Partner at the ALS Investment Fund further comments: “we are very happy that Orphazyme has raised such a significant amount today, and will dedicate a major part of this new funding to its ALS related clinical program. With this the company can potentially bring a new therapy to a space with a huge clinical unmet need”.

### **About Orphazyme ApS**

Orphazyme ApS is a Danish biotech company that develops paradigm-changing medicines for the treatment of protein misfolding diseases with well-characterized mechanisms of disease. Their lead program is in development as a treatment for the lysosomal storage disease Niemann-Pick disease type C. This is one of a family of ~50 debilitating genetic disorders, which often affect children, where most of these diseases are currently untreatable. For more information, please visit [orphazyme.com](http://orphazyme.com).

### **About ALS Investment Fund**

The ALS Investment Fund supports and finances biotech companies that develop drugs and diagnostics for Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neuron Disease and Lou Gehrig’s disease in the US. The Fund was initiated by 3 Dutch ALS patients and is supported by a top-tier European VC firm, Life Science Partners. The ALS Investment Fund invests globally, but focuses on Europe and the US. The fund brings depth of disease-specific knowledge and a broad network in the space to the companies it invests in. More information is available at [alsinvestmentfund.com](http://alsinvestmentfund.com).

### **About LSP**

LSP is an independent European investment firm, providing financing for private and public life sciences companies. LSP’s mission is to connect investors to inventors, focusing on unmet medical needs. Since the late 1980s, LSP’s management has invested in about 100 innovative enterprises, many of which have grown to become leaders of the global life sciences industry. With over €1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s leading life sciences investors. For more information, please visit [lspvc.com](http://lspvc.com)

### **Contact:**

SUNU Ventures BV  
Johannes Vermeerplein 9  
1071 DV Amsterdam  
The Netherlands  
[contact@alsinvestmentfund.com](mailto:contact@alsinvestmentfund.com)